INNOVAPATH™
The Premier Journal Bridging Discovery & Innovation

Brief Report
https://doi.org/10.63501/bfkae187

The Antimicrobial Potential of Virophages Against Multidrug-Resistant Bacteria

Muhammad Talha[1], Laiba Shamim[2]

[1]MBBS, King Edward Medical University, Lahore, Pakistan.

[2]MBBS, Jinnah Sindh Medical University, Karachi, Pakistan.

[2]Corresponding Author Email: Laibashamim015@gmail.com

ABSTRACT:

Antimicrobial resistance is becoming a danger to global health as it has caused more than 1.27 million deaths in 2019 alone. Traditional antibiotics are becoming less and less effective when it comes to multidrug-resistant (MDR) organisms like Klebsiella pneumoniae and Pseudomonas aeruginosa. A promising substitute is provided by engineered virophage therapy, that makes use of genetically altered bacteriophages. By interfering with genes that provide resistance, these virophages lyse bacteria and integrate into their defense mechanisms. Recent developments show they can reverse resistance traits and eradicate MDR bacteria. Studies on animals have demonstrated a notable decrease in bacterial load and an increase in survival. In contrast to traditional antibiotics, virophages change with bacterial populations, which may postpone the formation of resistance and protect the human microbiome. There are still issues, nevertheless, such as intricate host-phage dynamics and a lack of regulatory frameworks. However, to validate efficacy, large-scale trials are needed. Engineered virophages should be given priority in global antimicrobial stewardship initiatives since they are a breakthrough step in the fight against superbugs.

DISCUSSION:

Antibiotic resistance is probably one of the greatest threats contemporary medicine has to face. Multidrug-resistant (MDR) bacteria probably led to 1.27 million deaths throughout the world in 2019 alone, and this figure undoubtedly will inflate rapidly if newer modalities do not come into existence soon (1). Early generation antibiotics would lessen effectiveness against novel strains of superbugs such as carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa. This implies that new medicines have to be invented. Recent innovations of engineered virophage therapies have been produced to neutralize resistant bacteria. These therapies employ genetically modified bacteriophage agents and have been identified as viable magic bullets in combating antimicrobial resistance.

Bacteriophages (phages) are viruses that infect only bacteria and leave human cells and their commensal microbiota unharmed. Engineered phages can integrate into the bacterial defense systems, such as CRISPR-Cas, and deliver genetic lethality or the genes that are disrupting the proteins which confer resistance (2). The amazing discovery has been released in April 2025; redesigning virophages can potently attack the MDR strains of Pseudomonas aeruginosa, taking over their replication machinery to lyse these bacteria and degrade their antibiotic resistance genes simultaneously and thus effectively reversing their resistance phenotypes (3). This combined mode of action uniquely identifies virophage therapy as unlike traditional

antibiotics and previous initial efforts in phage therapy that suffered from bacterial immunity and narrow host ranges.

Experimental evidence is strongly in support of the clinical potential of virophages. In mouse infection studies, a cocktail of phages targeting Klebsiella pneumoniae and Acinetobacter baumannii resulted in a substantial reduction in bacterial load and increased survival compared to untreated controls (4). Since phages co-evolve with bacterial populations, resistance development in phages may occur at a slower pace than antibiotics, therefore allowing flexible and sustainable treatment schedules. Furthermore, the specificity inherent in phage therapy protects the host microbiome, thereby reducing the likelihood of secondary infections and dysbiosis associated with broad-spectrum antibiotics.

Although many advances have been made, some challenges still exist in the full development of virophage therapy. First, the complexity of the phage-host interaction requires extensive characterization so that efficacy and safety can be guaranteed across diverse patient populations. Second, regulatory pathways through which phage therapeutics could receive approval are currently under development; hence, large randomized clinical trials are desperately needed to provide direction for standardization in dosing and delivery methods as well as long-term effects (5). Funding agencies, policymakers, and clinicians should design and integrate virophage research into antimicrobial stewardship programs.

CONCLUSION:

In summary, engineered virophage therapies represent a new ingenious avenue of approach for treating superbugs, some of which manifest antibiotic resistance. I request the medical research community to give further consideration to this area of scientific inquiry for interdisciplinary collaboration to remove barriers. Virophage therapy would herald a new era in the management of infectious diseases and reduce the global burden of antimicrobial resistance.

REFERENCES

1. Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–655. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8841637 IF: 98.4 Q1 B1/
2. Dedrick RM, Guerrero-Bustamante CA, Garlena RA, Russell DA, Ford K, Harris K, et al. Engineered bacteriophages for the treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus. Nat Med. 2019;25(5):730–3.
3. Law N, Logan C, Yung G, et al. Personalized inhaled bacteriophage therapy for treatment of multidrug-resistant Pseudomonas aeruginosa in cystic fibrosis. Nat Med [Internet]. 2025 [cited 2025 May 15]; Available from: https://www.nature.com/articles/s41591-025-03678-8
4. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162–73.
5. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage. 2011;1(2):66–85.

Disclosure of contributions:

Muhammad Talha: Conceptualization, Design, and Manuscript Writing
Laiba Shamim: Manuscript Writing and Critical Review

Acknowledgements: None

Financial support: None

Conflicts of Interest: The authors declare no conflicts of interest.